Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Account Payables
Amounts the company owes suppliers for goods and services received.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Account Payables · Q4 FY2025 · quarter ended Dec 2025
Account payables remains negative
Q4 FY2025 account payables was $0, compared with $1.63M a year earlier.
Context
- Account payables amounted to 0.0% of total assets at the end of Q4 FY2025, down 8.6 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.63M | +96.5% |
| FY2023 | 2023-12-31 | 827.15K | -41.3% |
| FY2022 | 2022-12-31 | 1.41M | -25.5% |
| FY2021 | 2021-12-31 | 1.89M | — |
Account Payables vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 9, against a peer median of +13.6%.
- Account payables amounts to 0.0% of total assets for NNNN, versus a peer median of 4.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $790M USD | -18.9% | +7.1% | 6.0% | |
| Mar 2026 | $52.3M USD | +13.7% | -6.5% | 5.0% | |
| Mar 2026 | CA$51.76M CAD | — | +42.1% | 3.9% | |
| Feb 2026 | $29.11M USD | -3.8% | +5.9% | 11.2% | |
| Mar 2026 | $11.66M USD | +10.7% | +9.6% | 8.6% | |
| Mar 2026 | $10.88M USD | +26.7% | +47.3% | 2.0% | |
| Mar 2026 | $10.82M USD | +219.3% | +59.8% | 8.4% | |
| Dec 2025 | $8.27M USD | — | — | 2.5% | |
| Mar 2026 | $4.49M USD | +13.5% | -31.6% | 0.9% | |
| Mar 2026 | $2.33M USD | +91.6% | +66.5% | 2.5% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | -100.0% | — | 0.0% |
| Peer median (excluding NNNN) | — | +13.6% | +9.6% | 4.5% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.